Associated factors of difficult-to-treat spondyloarthritis

Authors

  • Séiny Kanta Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Najlae El Ouardi Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Mahamadou Sagara Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Houda El Assad Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Hajar Zouaki Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • El Kacem El Marbouh Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Alassane Alidou Garba Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Abdellah Ould Mohamed Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Laila Taoubane Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Abderrahim Majjad Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Hamza Toufik Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.
  • Ahmed Bezza Rheumatology Department, Mohammed V Military Teaching Hospital – PO Box 1018, Rabat; Faculty of Medicine and Pharmacy, PO Box 6203, Rabat Institute, Mohammed V University, Rabat, Morocco.

DOI:

https://doi.org/10.62438/tunismed.v104i05.6683

Keywords:

Spondyloarthritis, Targeted therapy, Difficult to treat, Associated factors

Abstract

Introduction: Biotherapies have revolutionised the management of spondyloarthritis (SpA). Despite these advances, there is still a proportion of patients with multiple changes in biological markers, which may correspond to difficult-to-treat spondyloarthritis (SPA D2T). Our study aims to
explore the prevalence of this particular entity and to characterise its clinical aspects in a Moroccan population.
Methods: This is a comparative cross-sectional study that included patients with SpA admitted to the department on biologic therapies. Sociodemographic, comorbidity, clinical, paraclinical and therapeutic data were collected. Patients who had received at least two biologics were considered to be SpA D2T. A comparison was made with a control group of non-multi-switchers (SpA-non-D2T).
Results: 210 patients were included, 56.2% of whomwere men. The prevalence of multi-switchers was 32,7%. D2T SpA patients were predominantly female (53,6% versus 39%, p= 0,04), had more axial involvement (76,8% versus 91,5%, p= 0,003), CsDMARD use (97,1% versus 31,9%, p= < 0,001).
Disease activity at the initiation of biotherapy was higher in D2T-ASDs. The time between diagnosis and use of the first biologic was longer (4[2,25–6] years versus 3 [1–4] years, p = 0,03). All D2T-SPA patients had received anti-TNFα.
Conclusion: Our study found a high prevalence of D2T-SpA.

Downloads

Download data is not yet available.

References

Pham T, Curmin R, Flachaire B, Pinto S, Richard CM, Tubach F. Les multiples changements de thérapies ciblées sont fréquents chez

les patients atteints de spondyloarthrite : étude des données du Système national des données de santé (SNDS). Rev Rhum. 1 déc

;90:A196-7.

Les spondyloarthrites difficiles à prendre en charge - ClinicalKey [Internet].[cité16juill2025].Disponiblesur:https://www.clinicalkey.

fr/#!/content/journal/1-s2.0-S1169833025000262?scrollTo=%231- s2.0-S1169833025000262-gr1

Delépine T, Philippe P, Houvenagel E, Deprez X, Taisne N, Pascart T, et al. Patients atteints de spondyloarthrite axiale « difficile à

traiter » : définition et caractéristiques cliniques. Rev Rhum. 1 déc 2022;89:A74.

Masson E. EM-Consulte. [cité 1 juill 2024]. Le concept de maladie difficile à traiter (D2T) est-il applicable à la spondyloarthrite axiale ?

Disponible sur: https://www.em-consulte.com/article/1632891/le- concept-de-maladie-difficile-a-traiter-d2t-est-

Masson E. EM-Consulte. [cité 30 juin 2024]. Spondyloarthrites difficiles à traiter : quelles caractéristiques ? Disponible sur: https://

www.em-consulte.com/article/1634421/spondyloarthrites- difficiles-a-traiter�-quelles-ca

Amazon.fr - Rhumatologie: Réussir son DFASM - Connaissances clés - COFER - Livres [Internet]. [cité 15 avr 2024].

Disponible sur: https://www.amazon.fr/Rhumatologie-R%C3%A9ussir-DFASM-Connaissances-cl%C3%A9s/dp/2294769759/crid=2Y76Z29YTQFAP&dib=eyJ2IjoiMSJ9. Ro_9ivsfAX8Tqv9ciIDrTYwsv3Yv6AxcRSbN_Fk7gkd

KpMOw34cYA84NZoCDlzjYba8zIk5EcnAVD91n-Kw. C6O5nAmzTi1oicRtnXvKWXJ6wwlE_h2mTF55WpFBNXU&dib_ er%2Caps%2C633&sr=8-1

Darrieutort-Laffite C. Pathologies rares pouvant simuler une spondyloarthrite ou chevaucher avec celle-ci. Rev Rhum Monogr.

sept 2018;85(4):267-73.

Grange L, Carton L, Dachicourt JN, Diebold R, Faugère M, Froukhi A, et al. Recommandations de la Société française de rhumatologie

(SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite : version adaptée à une utilisation par

les patients. Rev Rhum. mars 2016;83(2):110-5.

Fautrel B, Belhassen M, Hudry C,Woronoff-Lemsi MC, Levy-Bachelot L, Van Ganse E, et al. Predictive factors of tumour necrosis inhibitor

treatment persistence for rheumatoid arthritis: An observational study in 8052 patients. Joint Bone Spine. 1 mai 2020;87(3):267-9.

Blanchais A, Moltó A, Dougados M. Comorbidités et spondyloarthrite. Rev Rhum Monogr. sept 2014;81(4):244-8.

Edition S. L’ASAS publie sa définition de la spondyloarthrite axiale difficile à prendre en charge - RhumatoNet [Internet].

[cité 16 juill 2025]. Disponible sur: https://www.mediscoop.net/rhumatologie/index.e5200943297b847e539bfc4ba69c72&id_

midn=21680&from=newsletter

Zemrani S, Amine B, Elbinoune I, Charoui C, Rostom S, Rachid B. Spondyloarthrites difficiles à traiter : quelles caractéristiques ? Rev

Rhum. 1 déc 2023;90:A190-1.

Pham T, Curmin R, Flachaire B, Pinto S, Richard CM, Tubach F. Les multiples changements de thérapies ciblées sont fréquents chez

les patients atteints de spondyloarthrite : étude des données du Système national des données de santé (SNDS). Rev Rhum. 1 déc

;90:A196-7.

Benavent D, Capelusnik D, van der Heijde D, Landewé R, Poddubnyy D, van Tubergen A, et al. How is early spondyloarthritis defined in

the literature? Results from a systematic review. Semin Arthritis Rheum. 1 août 2022;55:152032.

Pham T, Flachaire B. Quelle place pour les associations de traitements ciblés ? Rev Rhum. 1 déc 2022;89:A7-9.

Berre CL, Loeuille D, Peyrin-Biroulet L. Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis

and Spondyloarthropathy. Clin Gastroenterol Hepatol. 1 mars 2019;17(4):794-6.

Poddubnyy D, Navarro-Compán V, Torgutalp M, Arends S, Aydin SZ, Battista S, et al. The Assessment of SpondyloArthritis International

Society (ASAS) Consensus-Based Expert Definition of Difficult-to- Manage, including Treatment-Refractory, Axial Spondyloarthritis.

Ann Rheum Dis. avr 2025;84(4):538-46.

Fardeau et déterminants de l’échec des traitements de fond multib/ tsDMARD dans le rhumatisme psoriasique | Arthritis Research &

Therapy [Internet]. [cité 22 déc 2025]. Disponible sur: https://link.springer.com/article/10.1186/s13075-025-03518-7

Mease PJ, Husni ME, Siegel E, Furst DE, Mcilraith M, Strand V, et al. What Matters in Psoriatic Arthritis: A Comparison of

Patient and Clinician Perspectives. ACR Open Rheumatol. janv 2025;7(1):e11781.

Novell G, Azuaga AB, Alascio L, Omaña O, Arango C, Peñafiel- Sam J, et al. Clinical and Ultrasound Characteristics of a Difficult-

to-Treat Psoriatic Arthritis Population. Diagnostics. 23 sept 2025;15(19):2418

Additional Files

Published

2026-05-24

Issue

Vol. 104 No. 05 (2026): Tunis Med May 2026

Section

Original articles

Categories

License

Copyright (c) 2026 La Tunisie Médicale

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.